Tag: Prescription Drugs
Review: ß-Blocker Therapy Not Linked to Depression
ß-blocker therapy possibly associated with unusual dreams, insomnia, and sleep disorders
2021 KDIGO Guideline Lowers Target Systolic BP for Adults With CKD
69.5 percent of adults with CKD eligible for BP lowering according to 2021 KDIGO guideline versus 49.8 percent with 2012 guideline
ASA: Adding Icosapent Ethyl to Statin Further Cuts Stroke Risk
Event rates for time to first fatal or nonfatal stroke significantly reduced for IPE versus placebo
Teplizumab Could Delay Diagnosis of Type 1 Diabetes
Teplizumab improves beta-cell function in high-risk individuals with relatives who have type 1 diabetes
Tocilizumab Use Not Supported for Moderate-to-Severe COVID-19
Progression of COVID-19 up to day 14 did not differ with addition of tocilizumab to standard care in Phase 3 trial conducted in India
CNS-Active Polypharmacy Examined in Seniors With Dementia
Most common medication was gabapentin, which was linked to 33.0 percent of polypharmacy-days
AAN: Fetal Exposure to Antiseizure Meds Has No Neuropsychological Impact
No difference found in primary outcome of Verbal Index score at age 3 years with fetal exposure to ASM or for those born to healthy women
Medicare Payments for Brand-Name Neurology Meds Soaring
From 2013 to 2017, number of claims increased 7.6 percent, but total payments increased 50.4 percent
FDA Warns Consumers to Not Use Ivermectin for COVID-19
Agency has received reports of patients requiring medical support after self-medicating with ivermectin for use in horses
Targeted Albumin Not Better for Hospitalized Cirrhosis Patients
No difference in incidence of end-point events, but more adverse events, seen in targeted albumin group versus standard-care group
